India vs Latvia: Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati
India
97.0%
in 2025
Latvia
97.0%
in 2025
India rank
17th
Latvia rank
17th
Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati over time
- India
- Latvia
How they compare
India currently reports 97.0% against 97.0% in Latvia, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Latvia ahead.
India ranks 17th and Latvia ranks 17th of 194 countries.
Latvia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | India | Latvia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 2.1% | 72.6% | 70.5% | Latvia |
| 2020s | 64.5% | 92.3% | 27.8% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati, India or Latvia?
- India, at 97.0% against 97.0% in Latvia as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati between India and Latvia?
- 0.0%, with India ahead.
- How many years of comparable data are there for India and Latvia?
- 18 years are reported by both, from 2008 to 2025.
- How do India and Latvia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati?
- India ranks 17th and Latvia ranks 17th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.